Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Controlled Clinical Trial of Chidamide Combined With Venetoclax and Azacitidine in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Not Suitable for Intensive Chemotherapy

NCT06386302 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.

NCT NCT06386302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06386302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Controlled Clinical Trial of Chidamide Combined With Venetoclax and Azacitidine in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Not Suitable for Intensive Chemotherapy
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Not applicable
Overall status
Recruiting
Start date
August 5, 2024
Completion date
December 30, 2027
Enrollment
184 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, aml